Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by Sarb99on Mar 18, 2021 12:49pm
141 Views
Post# 32826595

People selling after the news & moving on, nothing wrong

People selling after the news & moving on, nothing wrong
That is called a person with class, you guys did not like what you see. You sold and move on rather than whining. Do deserve respect. 
 
Revenue from the first quarter maybe not as good as we hoped for but not that bad either. January revenue 73,973x$96 =USD 7,101,408 from collection sites, USD 2.1 million from the Kinross deal and 30,717x$98 =USD 3,010,266 in February. 
 
So, total revenue for the first quarter is $7,101,408 +$2,100,000+$3,010,266 =$12,211,674. Once we convert this amount to Canadian as Medivolve is a Canadian company and trading on the Canadian exchange. $12,211,674x1.24=$15,142,475
 
We knew revenue maybe not as much when they put some of the collection sites temporarily closed. I was hoping revenue to be somewhere close to $30 million for the first quarter but it seems, we will be close to $20 million. This is not bad when you compare it to the market cap and new business. Year-end financial should also show some revenue. 
<< Previous
Bullboard Posts
Next >>